larotrectinib
NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling
The guidelines recognize the importance of molecular profiling in diagnosing, treating, and identifying clinical trial opportunities for children with high-grade gliomas.
The analysis of three clinical trials also suggested that NTRK fusion-positive colorectal cancers don't respond as well as other tumors to Rozlytrek.
CHOP Researchers Find Gene Fusions are Harbingers of Aggressive Disease in Pediatric Thyroid Cancer
Premium
The findings could have treatment implications and encourage greater comprehensive genomic profiling in more young cancer patients.
Bayer, OncoDNA, Tamkin Al-Seha Medical Partner to Offer NTRK Fusion Testing in Saudi Arabia
The partnership aims to test 1,000 advanced cancer patients in the country to determine their eligibility for the TRK inhibitor larotrectinib.
In a recently published study, researchers found NTRK fusions were more common in pediatric than adult tumors and testing for them helped diagnose rare tumors.